Literature DB >> 25003725

Heterogeneity of phenotypic characteristics of the modern and ancestral Beijing strains of Mycobacterium tuberculosis.

Kiatichai Faksri1, Angkana Chaiprasert, Clarie Pardieu, Nicola Casali, Tanapat Palaga, Therdsak Prammananan, Prasit Palittapongarnpim, Naraporn Prayoonwiwat, Francis Drobniewski.   

Abstract

BACKGROUND: The Beijing strain of Mycobacterium tuberculosis (MTB) is of great concern because this hypervirulent strain has caused numerous tuberculosis outbreaks. However, the mechanisms that allow the MTB Beijing strain to be highly pathogenic remain unclear and previous studies have revealed heterogeneity within this family.
OBJECTIVE: To determine the association between some phenotypic characteristics and phylogroups of the Beijing strain of MTB.
METHODS: Eight Beijing strains, 5 modern and 3 ancestral sublineages, were selected from the phylogroups of MTB. The selection was based on copy number of IS6110 at NTF, region of differences, and single nucleotide polymorphisms. The abilities of these strains to grow intracellularly in THP-1 macrophages, to induce apoptosis, necrosis, and cytokines production were examined using quantitative real-time PCR and commercially available ELISA kits, respectively.
RESULTS: There were some significant differences between the two sublineages of the Beijing strain of MTB. The ancestral Beijing sublineages showed higher intracellular growth rates (p < 0.05) and necrosis induction rates (p < 0.01) than the modern Beijing sublineages. By contrast, the modern Beijing sublineages induced lower apoptosis and protective cytokine responses, i.e., TNF-α (p < 0.05) and IL-6 (p < 0.01) and higher non-protective IL-10 response. The modern Beijing sublineages may have evolved so that they have greater ability to diminish host defense mechanisms. The slower growth rate and reduced necrosis induction in host cells might allow the bacteria to cause a persistent infection.
CONCLUSION: The results revealed a phylogroup-associated heterogeneity of phenotypes among MTB Beijing sublineages.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25003725     DOI: 10.12932/AP0361.32.2.2013

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  5 in total

1.  Correlates between models of virulence for Mycobacterium tuberculosis among isolates of the Central Asian lineage: a case for lysozyme resistance testing?

Authors:  Claire Pardieu; Nicola Casali; Simon O Clark; Richard Hooper; Ann Williams; Preya Velji; Ximena Gonzalo; Francis Drobniewski
Journal:  Infect Immun       Date:  2015-03-16       Impact factor: 3.441

2.  Mycobacterium tuberculosis Type II Toxin-Antitoxin Systems: Genetic Polymorphisms and Functional Properties and the Possibility of Their Use for Genotyping.

Authors:  Marina V Zaychikova; Natalia V Zakharevich; Maria O Sagaidak; Nadezhda A Bogolubova; Tatiana G Smirnova; Sofya N Andreevskaya; Elena E Larionova; Maria G Alekseeva; Larisa N Chernousova; Valery N Danilenko
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

3.  Whole-genome comparative analysis at the lineage/sublineage level discloses relationships between Mycobacterium tuberculosis genotype and clinical phenotype.

Authors:  Andrea Monserrat Negrete-Paz; Gerardo Vázquez-Marrufo; Ma Soledad Vázquez-Garcidueñas
Journal:  PeerJ       Date:  2021-09-08       Impact factor: 2.984

4.  Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese.

Authors:  Tao Luo; Iñaki Comas; Dan Luo; Bing Lu; Jie Wu; Lanhai Wei; Chongguang Yang; Qingyun Liu; Mingyu Gan; Gang Sun; Xin Shen; Feiying Liu; Sebastien Gagneux; Jian Mei; Rushu Lan; Kanglin Wan; Qian Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

5.  Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.

Authors:  Yi Hu; Qi Zhao; Jim Werngren; Sven Hoffner; Vinod K Diwan; Biao Xu
Journal:  BMC Infect Dis       Date:  2016-01-07       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.